Pfizer nabs equity stake in Swiss biotech working on celiac therapy; Verona gets more cash after COPD win
Pfizer is investing in new treatments for celiac disease.
The Big Pharma shelled out $35 million in equity for Anokion, a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.